Measuring Oestrogen Receptor Beta in Breast Cancer
Author Information
Author(s): Speirs V, Carder P J, Lansdown M R J
Primary Institution: Molecular Medicine Unit, Clinical Sciences Building, St James's University Hospital, Leeds
Hypothesis
Why do different studies report varying levels of ERβ positivity in breast tumors?
Conclusion
The study highlights the need for a consensus on measuring ERβ in breast cancer due to divergent results from similar cohorts.
Supporting Evidence
- Previous studies reported varying levels of ERβ positivity in breast tumors.
- Different monoclonal antibodies may affect the detection of ERβ.
- A consensus on measuring ERβ is necessary for clinical relevance.
Takeaway
Scientists are trying to figure out how to measure a special protein in breast cancer, but different methods are giving different results.
Methodology
The study involved immunohistochemical detection of ERβ in breast tumors using different monoclonal antibodies.
Potential Biases
Potential bias due to the use of different antibodies in the studies.
Limitations
The study does not establish a clear consensus on the best way to measure ERβ.
Participant Demographics
Breast cancer patients from Scottish and English cohorts.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website